Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000256588 | SCV000324668 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-10-18 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000256588 | SCV000327898 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000496945 | SCV000592195 | likely pathogenic | Hereditary breast ovarian cancer syndrome | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV002446506 | SCV002676706 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-26 | criteria provided, single submitter | clinical testing | The p.R2824* pathogenic mutation (also known as c.8470A>T), located in coding exon 18 of the BRCA2 gene, results from an A to T substitution at nucleotide position 8470. This changes the amino acid from an arginine to a stop codon within coding exon 18. This alteration was identified in a large, worldwide study of BRCA1/2 mutation positive families (Rebbeck TR et al. Hum Mutat, 2018 05;39:593-620). Additionally, this alteration was identified in an individual diagnosed with breast and/or ovarian cancer from China (Bhaskaran SP et al. Int J Cancer, 2019 08;145:962-973). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Research Molecular Genetics Laboratory, |
RCV000496945 | SCV000587955 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research |